Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

EXTEND (Eltrombopag Extended Dosing Study) (EXTEND)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT00351468
First received: July 10, 2006
Last updated: March 5, 2017
Last verified: March 2017
  Purpose
An open-label, dose-adjustment, extension study to evaluate the safety and efficacy of eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP) who have previously been enrolled in an eltrombopag trial. This study will allow adjustment of the eltrombopag dose to achieve an individualized dose and schedule for each subject. In addition, the ability to reduce the dose of concomitant ITP medications in the presence of eltrombopag, while maintaining platelet counts = 50,000/μL will be investigated.

Condition Intervention Phase
Purpura, Thrombocytopaenic, Idiopathic
Drug: eltrombopag olamine (SB-497115-GR)
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: EXTEND (Eltrombopag Extended Dosing Study): An Extension Study of Eltrombopag Olamine (SB-497115-GR) in Adults, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study.

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Overall Summary of On-Therapy Adverse Events (Safety Population) [ Time Frame: Start date was the first dose of investigational product and up to the day after the last dose . Post-therapy: start date was more than 1 day after the last dose and up to 30 days after last dose of investigational product up to week 364 ]
    All safety evaluation findings considered to be adverse events are reported in the Adverse Event section.


Secondary Outcome Measures:
  • Subjects Achieving Maximum Platelet Counts Greater Than or Equal to 30 Gi/L or 50 Gi/L in the Absence of Rescue Medication [ Time Frame: Baseline up to 2 years ]

    Subjects who achieved maximum platelet count at least once during treatment. All platelet counts after an on-study splenectomy are not classed as responses.

    Platelet counts within 7 days after a platelet transfusion are not classed as responses.

    Platelet counts while taking an increased ITP medication or within 6 weeks after the end of an increased ITP medication are not classed as responses.


  • Summary of Subjects Achieving Platelet Count Levels by Week, in the Absence of Rescue Medication [ Time Frame: Baseline up to Year 7/Week 364 ]

    If a subject has more than 1 platelet count result within a week, the lowest value observed is used to determine response. All platelet counts after an on-study splenectomy are not classed as responses. Platelet counts within 7 days after a platelet transfusion are not classed as responses.

    Platelet counts while taking an increased ITP medication or within 6 weeks after the end of an increased ITP medication are not classed as responses.


  • Number of Subjects Who Responded to Eltrombopag in a Previous Study and Who Respond to Retreatment With a Rise in Platelet Count to Either ≥ 50,000/µL or ≥30,000/µL [ Time Frame: Baseline up to 2 years ]
    Responder in TRA100773: Platelet count 50 Gi/L and 2 x baseline (BL) at last on-treatment assessment. Responders in EXTEND: Platelet count 50 Gi/L and 2 x baseline (BL), 50 Gi/L, and 30 Gi/L at any time. Responder in RAISE: Platelet count 50GI/L and 2 x baseline at Week 6 assessment. Responders in EXTEND: Platelet count 50 Gi/L and 2 x baseline, 50 Gi/L, and 30 Gi/L at any time. Responder in REPEAT: Platelet count 50 GI/L and 2 x baseline (BL) at Week 6 assessment in Cycle 1. Responders in EXTEND: Platelet count 50 Gi/L and 2 x baseline (BL) 50 Gi/L, and 30 Gi/L at any time.

  • Number of Participants With Reduction and/or Sparing of Concomitant ITP Therapies, While Maintaining a Platelet Count ≥ 50,000/mL. [ Time Frame: Baseline up to 2 years ]
    Sustain reduct: Sustained reduction 1 Denominator is number of subjects taking an ITP medication at baseline. 2 Denominator is number of subjects with a sustained reduction. Note: Sustained reduction defined as reduction from baseline in dose and/or frequency which is maintained for at least 4 weeks. Excludes sustained reductions started more than 1 day after last dose.

  • Number of Subjects Who Required Rescue Therapy During Treatment With Eltrombopag. [ Time Frame: Baseline up to 2 years ]
    Rescue treatment is defined as a composite of: new ITP medication, increased dose of a concomitant ITP medication, platelet transfusion, and splenectomy. Subjects may have received more than 1 type of rescue therapy

  • Maximum ITP Bleeding Score at Any Time During the Study During All Stages. [ Time Frame: Baseline up to 2 years ]
    The ITP bleeding score is a tool which has been designed specifically to assess the bruising and bleeding in patients with ITP across body sites, ranging from mild to severe. The WHO Grades were dichotomized into the following categories: - Grade 0, No bleeding -Grade 1 to 4, Any bleeding -Grade 0 to 1: No clinically significant bleeding -Grade 2 to 4 Clinically significant bleeding

  • Best Post-Baseline Change in SF-36v2 Questionnaire Score From Any Time Point Compared With Baseline [ Time Frame: Baseline, beginning of each stage, change in therapy and minimum frequency of every 3 months during stages, prior to early discontinuation, up to 2 years ]
    The SF-36v2 assessment tool was used to obtain information about subjects' general health status and health-related quality of life. Until a formal assessment of minimal clinically important differences (MCID) is performed, changes from baseline of more than 0.5 standard deviations are suggested as clinically meaningful. Scores were transformed to a 0-100 point scale, with higher scores representing more positive answers. Scores were normalized to have a mean of 50 and SD of 10 to allow for comparison with outcomes from other chronic diseases. Recall period is the past week prior to administration. The change in scores was measured at the transitioning period and immediately prior to withdrawal/completion over 2 years, and the mean of these measurements was recorded to calculate the change from baseline and the best post baseline change score was reported for the entire group

  • Best Post-Baseline Change in the Short Form of the Motivation and Energy Scale (MEI-SF) From Any Time Point Compared With Baseline [ Time Frame: Baseline, beginning of each stage, change in therapy and minimum frequency of every 3 months during stages, prior to early discontinuation, up to 2 years ]
    The MEI-SF (18 questions) was used to measure the reductions in mental energy, physical energy, and social motivation, either as symptoms of chronic ITP or as a side effect of pharmacotherapy. Minimal clinically important differences are estimated as 0.5 standard deviations or 7.5 points. All items use either a 7-level (0 to 6) or 5-level (0 to 4) response scale; items with a 5-level response scale were rescaled to 7-levels, and items were reverse-scored as necessary such that higher scores represent higher HRQoL Total score ranges from 0 to 108 points. Recall period is past week prior to administration. The change in scores was measured at the transitioning period and immediately prior to withdrawal/completion over 2 years, and the mean of these measurements was recorded to calculate the change from baseline and the best post baseline change score was reported for the entire group

  • Best Post-Baseline Change in the FACIT-Fatigue 13 Item Subscale Score From Any Time Point Compared to Baseline [ Time Frame: Baseline, beginning of each stage, change in therapy and minimum frequency of every 3 months during stages, prior to early discontinuation, up to 2 years ]

    The FACIT-Fatigue consists of 13 questions in which patients rate the frequency (0-4) of symptoms of fatigue, in terms of tiredness, weakness, and fatigue Items were reverse-scored as necessary such that higher scores represent higher HRQoL Total score ranges from 0 to 52.Using anchor-based estimates, the minimally important difference in this subscale is 3.0 points.

    Recall period is past week prior to administration. The change in scores was measured at the transitioning period and immediately prior to withdrawal/completion over 2 years, and the mean of these measurements was recorded to calculate the change from baseline and the best post baseline change score was reported for the entire group


  • Best Post-Baseline Change in the FACT-TH6 at Any Time Point Compared to Baseline [ Time Frame: Baseline, beginning of each stage, change in therapy and minimum frequency of every 3 months during stages, prior to early discontinuation, up to 2 years ]
    The FACT-TH6 consists of 6 questions in which patients rate (0-4) their general degree of worry related to bleeding and bruising, and resulting activity impairment and frustration. Although the six items do not constitute a formal domain or subscale of the FACT‑Th assessment tool, these items had been identified by focus groups of patients with chronic ITP as important indicators of their HRQoL. Items were reverse-scored as necessary such that higher scores represent higher HRQoL. Total scores ranged from 0 to 24. Recall period is not specified. The change in scores was measured at the transitioning period and immediately prior to withdrawal/completion over 2 years, and the mean of these measurements was recorded to calculate the change from baseline and the best post baseline change score was reported for the entire group


Enrollment: 302
Study Start Date: June 2006
Study Completion Date: July 2015
Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Eltrombopag
Open-label eltrombopag
Drug: eltrombopag olamine (SB-497115-GR)
Eltrombopag with starting dose of 50mg daily, max dose of 75mg daily and min dose of 25mg daily or less frequently. Modifications were given to maintain platelet count in range of 50 to 200 Gi/L.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject has signed and dated a written informed consent.
  • Adults (≥18 years) diagnosed with ITP according to the American Society for Hematology/British Committee for Standards in Haematology (ASH/BCSH) guidelines [George, 1996; BCSH, 2003]. In addition, a peripheral blood smear should support the diagnosis of ITP with no evidence of other disease causative of thrombocytopenia (e.g., pseudo thrombocytopenia, myelofibrosis). The physical examination should not suggest any disease which may cause thrombocytopenia other than ITP.
  • Prior completion of treatment and follow up periods in an ITP study of eltrombopag (e.g., TRA100773 or TRA102537/RAISE or TRA108057/REPEAT).
  • Subjects previously enrolled in Study TRA100773 must have completed the prescribed follow-up ophthalmic assessment at 6 months.
  • Subjects previously enrolled in TRA102537/RAISE or other studies that may lead into EXTEND (e.g., TRA108057/REPEAT) must have completed the treatment and follow-up periods as defined in that protocol.
  • Subject experienced no eltrombopag-related toxicity or other drug intolerance on prior eltrombopag study (e.g., TRA100773 or TRA102537/RAISE or TRA108057/REPEAT) even if resolved; subjects discontinued from previous study due to toxicity will not be eligible unless they received placebo.
  • Subject has no intercurrent medical event, including thrombosis.
  • Subjects must have either initially responded (platelet count > 100,000/mL) to a previous ITP therapy or have had a bone marrow examination consistent with ITP within 3 years to rule out myelodysplastic syndromes or other causes of thrombocytopenia
  • Previous therapy for ITP with immunoglobulins (IVIg and anti-D) must have been completed at least 1 week prior to first dose of study medication and the platelet count must show a clear downward trend after the last treatment with immunoglobulins. Previous treatment for ITP with splenectomy, rituximab and cyclophosphamide must have been completed at least 4 weeks prior to randomization, or clearly be ineffective.
  • Subjects treated with concomitant ITP medication (e.g. corticosteroids or azathioprine) must be receiving a dose that has been stable for at least 4 weeks prior to randomization. Subjects treated with cyclosporine A, mycophenolate mofetil or danazol must be receiving a dose that has been stable for at least 3 months prior to the first dose of study medication.
  • Prothrombin time (PT/INR) and activated partial thromboplastin time (aPTT) must be within 80 to 120% of the normal range with no history of hypercoagulable state.
  • A complete blood count (CBC), within the reference range (including WBC differential not indicative of a disorder other than ITP), with the following exceptions:
  • Hemoglobin: Subjects with hemoglobin levels between 10.0 g/dL and the lower limit of normal are eligible for inclusion, if anemia is clearly attributable to ITP (excessive blood loss).
  • ANC≥1500/mL (1.5 x 10^9/L) is required for inclusion (elevated WBC/ANC due to steroid treatment is acceptable).
  • The following clinical chemistries MUST NOT exceed the upper limit of normal (ULN) reference range by more than 20%: creatinine, ALT, AST, total bilirubin, and alkaline phosphatase. In addition, total albumin must not be below the lower limit of normal (LLN) by more than 10%.
  • Subject is practicing an acceptable method of contraception (documented in chart). Female subjects (or female partners of male subjects) must either be of non-childbearing potential (hysterectomy, bilateral oophorectomy, bilateral tubal ligation or post-menopausal > 1 year), or of childbearing potential and use one of the following highly effective methods of contraception (i.e., Pearl Index <1.0%) from two weeks prior to administration of study medication, throughout the study, and 28 days after completion or premature discontinuation from the study:
  • Complete abstinence from intercourse;
  • Intrauterine device (IUD);
  • Two forms of barrier contraception (diaphragm plus spermicide, and for males condom plus spermicide);
  • Male partner is sterile prior to entry into the study and is the only partner of the female;
  • Systemic contraceptives (combined or progesterone only).
  • Subject is able to understand and comply with protocol requirements and instructions.

Exclusion Criteria:

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

  • Any clinically relevant abnormality, other than ITP, identified on the screening examination, or any other medical condition or circumstance, which in the opinion of the investigator makes the subject unsuitable for participation in the study or suggests another diagnosis.
  • Concurrent malignant disease and/or history of cancer treatment with cytotoxic chemotherapy and/or radiotherapy.
  • Any prior history of arterial or venous thrombosis (stroke, transient ischemic attack, myocardial infarction, deep vein thrombosis or pulmonary embolism), AND≥two of the following risk factors: hormone replacement therapy, systemic contraception (containing estrogen), smoking, diabetes, hypercholesterolemia, medication for hypertension, cancer, hereditary thrombophilic disorders (e.g., Factor V Leiden, ATIII deficiency, etc), or any other family history of arterial or venous thrombosis
  • Pre-existing cardiovascular disease (including congestive heart failure, New York Heart Association [NYHA] Grade III/IV), or arrhythmia known to increase the risk of thromboembolic events (e.g. atrial fibrillation), or subjects with a QTc >450 msec.
  • Female subjects who are nursing or pregnant (positive serum or urine b-human chorionic gonadotrophin (b-hCG) pregnancy test) at screening or pre-dose on Day 1.
  • History of alcohol/drug abuse.
  • Treatment with an investigational drug within 30 days or five half-lives (whichever is longer) preceding the first dose of study medication.
  • Subject treated with drugs that affect platelet function (including but not limited to aspirin, clopidogrel and/or NSAIDs) or anti-coagulants for > 3 consecutive days within 2 weeks of the study start and until the end of the study.
  • History of platelet agglutination abnormality that prevents reliable measurement of platelet counts.
  • All subjects with secondary immune thrombocytopenia, including those with laboratory or clinical evidence of HIV infection, antiphospholipid antibody syndrome, chronic hepatitis B infection, hepatitis C virus infection, or any evidence for active hepatitis at the time of subject screening. If a potential subject has no clinical history that would support HIV infection or hepatitis infection, no further laboratory screening is necessary; however, standard medical practice would suggest further evaluation of patients who have risk factors for these infections.
  • A subject is planning to have cataract surgery.
  • In France, a subject is neither affiliated with nor a beneficiary of a social security category.

Other Eligibility Criteria Considerations:

To assess any potential impact on subject eligibility with regard to safety, the investigator must refer to the following document(s) for detailed information regarding warnings, precautions, contraindications, adverse events, and other significant data pertaining to the investigational product(s) being used in this study: CIB, SPM.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00351468

  Hide Study Locations
Locations
United States, Alabama
Novartis Investigative Site
Huntsville, Alabama, United States, 35805
Novartis Investigative Site
Mobile, Alabama, United States, 36608
United States, Arkansas
Novartis Investigative Site
Jonesboro, Arkansas, United States, 72401
United States, California
Novartis Investigative Site
Duarte, California, United States, 91010
Novartis Investigative Site
Los Angeles, California, United States, 90033
Novartis Investigative Site
San Francisco, California, United States, 94143
United States, Florida
Novartis Investigative Site
Miami, Florida, United States, 33136
United States, Georgia
Novartis Investigative Site
Atlanta, Georgia, United States, 30341
Novartis Investigative Site
Savannah, Georgia, United States, 31405
United States, Illinois
Novartis Investigative Site
Peoria, Illinois, United States, 61614
United States, Louisiana
Novartis Investigative Site
New Orleans, Louisiana, United States, 70115
United States, Massachusetts
Novartis Investigative Site
Boston, Massachusetts, United States, 02114
United States, Michigan
Novartis Investigative Site
Detroit, Michigan, United States, 48202
United States, Minnesota
Novartis Investigative Site
Brunsville, Minnesota, United States, 55337
United States, New Mexico
Novartis Investigative Site
Albuquerque, New Mexico, United States, 87109
United States, New York
Novartis Investigative Site
New York, New York, United States, 10021
United States, Ohio
Novartis Investigative Site
Cleveland, Ohio, United States, 44106
United States, Oregon
Novartis Investigative Site
Portland, Oregon, United States, 97227
United States, Texas
Novartis Investigative Site
Lubbock, Texas, United States, 79410
United States, Virginia
Novartis Investigative Site
Arlington, Virginia, United States, 22205
United States, Washington
Novartis Investigative Site
Seattle, Washington, United States, 98109
Novartis Investigative Site
Tacoma, Washington, United States, 98405
Novartis Investigative Site
Vancouver, Washington, United States, 98684
Australia, Australian Capital Territory
Novartis investigative Site
Garran, Australian Capital Territory, Australia, 2606
Australia, New South Wales
Novartis Investigative Site
Kogarah, New South Wales, Australia, 2217
Austria
Novartis Investigative Site
Vienna, Austria, A-1090
Canada, Ontario
Novartis Investigative Site
Hamilton, Ontario, Canada, L8S 4K1
Canada, Quebec
Novartis Investigative Site
Montreal, Quebec, Canada, H2L 4M1
Novartis Investigative Site
Montreal, Quebec, Canada, H3T 1E2
China
Novartis Investigative Site
Jiang Su Province, China, 215006
Novartis Investigative Site
Shanghai, China, 200025
Novartis Investigative Site
Tianjin, China, 300020
Czech Republic
Novartis Investigative Site
Brno, Czech Republic, 625 00
Novartis Investigative Site
Olomouc, Czech Republic, 775 20
Novartis Investigative Site
Praha 2, Czech Republic, 128 20
Denmark
Novartis Investigative Site
Odense, Denmark, 5000
Finland
Novartis Investigative Site
Kuopio, Finland, 70210
France
Novartis Investigative Site
Caen cedex 9, France, 14033
Novartis Investigative Site
Créteil, France, 94010
Novartis Investigative Site
Pessac, France, 33604
Germany
Novartis Investigative Site
Muenchen, Bayern, Germany, 80639
Novartis Investigative Site
Giessen, Hessen, Germany, 35392
Novartis Investigative Site
Hannover, Niedersachsen, Germany, 30159
Novartis Investigative Site
Hannover, Niedersachsen, Germany, 30625
Novartis Investigative Site
Saarbruecken, Saarland, Germany, 66113
Novartis Investigative Site
Berlin, Germany, 13353
Greece
Novartis Investigative Site
Athens, Greece, 10676
Novartis Investigative Site
Athens, Greece, 11525
Novartis Investigative Site
Thessaloniki, Greece, 57010
Hong Kong
Novartis Investigative Site
Shatin, New Territories, Hong Kong
Italy
Novartis Investigative Site
Bologna, Emilia-Romagna, Italy, 40138
Novartis Investigative Site
Albano Laziale (Roma), Lazio, Italy, 00041
Novartis investigative Site
Milano, Lombardia, Italy, 20132
Novartis Investigative Site
Padova, Veneto, Italy, 35128
Korea, Republic of
Novartis Investigative Site
Seoul, Korea, Republic of, 136-705
Netherlands
Novartis Investigative Site
Amersfoort, Netherlands, 3816 CP
Novartis Investigative Site
Amsterdam, Netherlands, 1105 AZ
Novartis Investigative Site
Den Haag, Netherlands, 2545 CH
Novartis Investigative Site
Nijmegen, Netherlands, 6525 GA
Novartis Investigative Site
Rotterdam, Netherlands, 3015 GE
New Zealand
Novartis Investigative Site
Auckland, New Zealand, 2024
Novartis Investigative Site
Christchurch, New Zealand, 8011
Novartis Investigative Site
Grafton, New Zealand, 1001
Novartis Investigative Site
Takapuna, Auckland, New Zealand, 0622
Pakistan
Novartis Investigative Site
Karachi, Pakistan, 75300
Novartis Investigative Site
Lahore, Pakistan, 54600
Peru
Novartis Investigative Site
Lima, Peru, Lima 27
Novartis Investigative Site
Lima, Peru, Lima 41
Poland
Novartis Investigative Site
Bialystok, Poland, 15-276
Novartis Investigative Site
Lodz, Poland, 93-510
Novartis Investigative Site
Lublin, Poland, 20-081
Novartis Investigative Site
Slupsk, Poland, 76-200
Novartis Investigative Site
Torun, Poland, 87-100
Novartis Investigative Site
Wroclaw, Poland, 50-367
Romania
Novartis Investigative Site
Bucharest, Romania, 022328
Novartis Investigative Site
Bucharest, Romania, 050098
Russian Federation
Novartis Investigative Site
Moscow, Russian Federation, 105 229
Novartis Investigative Site
Moscow, Russian Federation, 125167
Novartis Investigative Site
Novosibirsk, Russian Federation, 630087
Novartis investigative Site
St Petersburg, Russian Federation, 193024
Slovakia
Novartis Investigative Site
Kosice, Slovakia, 041 90
Novartis Investigative Site
Presov, Slovakia, 080 01
Slovenia
Novartis Investigative Site
Ljubljana, Slovenia, 1000
Spain
Novartis Investigative Site
Badalona/Barcelona, Spain, 08916
Novartis Investigative Site
Barcelona, Spain, 08025
Novartis Investigative Site
Madrid, Spain, 28006
Novartis Investigative Site
Madrid, Spain, 28007
Novartis Investigative Site
Palma de Mallorca, Spain, 07014
Novartis Investigative Site
Pamplona, Spain, 31008
Novartis Investigative Site
Santiago de Compostela, Spain, 15706
Sweden
Novartis Investigative Site
Göteborg, Sweden, SE-413 45
Novartis Investigative Site
Stockholm, Sweden, SE 171 76
Taiwan
Novartis Investigative Site
Taipei, Taiwan, 100
Thailand
Novartis Investigative Site
Bangkok, Thailand, 10330
Novartis Investigative Site
Khon Kaen, Thailand, 40002
Tunisia
Novartis investigative Site
Montfleury, Tunisia, 1008
Novartis investigative Site
Sfax, Tunisia, 3029
Novartis Investigative Site
Sousse, Tunisia, 4000
Novartis Investigative Site
Tunis, Tunisia, 1008
Ukraine
Novartis Investigative Site
Dnipropetrovsk, Ukraine, 49102
Novartis Investigative Site
Lviv, Ukraine, 79044
United Kingdom
Novartis Investigative Site
Plymouth, Devon, United Kingdom, PL6 8DH
Novartis Investigative Site
Taunton, Somerset, United Kingdom, TA1 5DA
Novartis Investigative Site
Liverpool, United Kingdom, L7 8XP
Novartis Investigative Site
London, United Kingdom, E1 1BB
Novartis Investigative Site
London, United Kingdom, NW1 2PG
Novartis Investigative Site
Manchester, United Kingdom, M13 9WL
Novartis Investigative Site
Reading, United Kingdom, RG1 5AN
Novartis Investigative Site
Swansea, United Kingdom, SA6 6NL
Vietnam
Novartis Investigative Site
Ho Chi Minh, Vietnam
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00351468     History of Changes
Other Study ID Numbers: TRA105325
Study First Received: July 10, 2006
Results First Received: July 6, 2016
Last Updated: March 5, 2017

Keywords provided by Novartis:
eltrombopag olamine
SB-497115-GR
idiopathic thrombocytopenic purpura
thrombocytopenia
ITP
platelets

Additional relevant MeSH terms:
Purpura
Purpura, Thrombocytopenic
Purpura, Thrombocytopenic, Idiopathic
Blood Coagulation Disorders
Hematologic Diseases
Hemorrhage
Pathologic Processes
Skin Manifestations
Signs and Symptoms
Thrombotic Microangiopathies
Thrombocytopenia
Blood Platelet Disorders
Immune System Diseases
Hemorrhagic Disorders
Autoimmune Diseases

ClinicalTrials.gov processed this record on May 25, 2017